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Objective: Care management is feasible to deploy in routine care, and the depression outcomes of patients
reached by this evidence-based practice are similar to those observed in randomized controlled trials.
However, no studies have estimated the population level effectiveness of caremanagement when deployed in
routine care. Population level effectiveness depends on both reach into the target population and the clinical
effectiveness for those reached.
Method: This multisite hybrid Type 3 effectiveness–implementation study employed a pre-post, quasi-
experimental design. The study was conducted at 22 Veterans Affairs community-based outpatient clinics.
Evidence-based quality improvement was used as the facilitation strategy to promote adoption. Medication
possession ratios (MPRs) were calculated for 1558 patients with an active antidepressant prescription.
Differences in treatment response rates at implementation and control sites were estimated from observed
differences in MPR.
Results: Reach into the target population at implementation sites was 10.3%. Patients at implementation sites
had a signiﬁcantly higher probability of having MPR≥0.9 than patients at control sites [odds ratio=1.38,
conﬁdence interval95=(1.07, 1.78), P=.01]. This increase inMPRwas estimated to yield a 1% point increase in
response rates.
Conclusions: While depression care management improves outcomes for patients receiving services, low
levels of reach can reduce overall population level effectiveness.
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Collaborative care management (CCM) is an evidence-based
practice that involves a multidisciplinary depression care team
providing guideline-concordant depression treatment in the primary
care setting. Mental health specialists (e.g., nurse care manager,
psychiatrist) support primary care providers by helping patients
overcome barriers to medication adherence, managing side-effects
and identifying nonresponders. Numerous randomized controlled
trials (RCTs) have demonstrated that CCM improves outcomes for
primary care patients treated for depression [1–9]. The CCM model
has been rolled out nationally in the United States by the Department
of Veterans Affairs (VA) as part of the Primary Care/Mental Health
Integration Initiative [10]. More recently, the VA has encouraged the
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(CBOCs), where half of VA primary care patients receive care.
However, there are numerous barriers to implementing a complex
clinical program like CCM in CBOCs that lack on-site mental health
specialists [11].
Two previous RCTs have documented that CCM can be successfully
adapted for primary care clinics lacking on-site mental health
specialists using telemedicine technologies [12,13]. While there is
good evidence that telemedicine-based CCM improves outcomes in
the context of an RCT, there is no evidence that it can improve
outcomes when implemented in routine care. We used an implemen-
tation facilitation method known as evidence-based quality improve-
ment (EBQI) to deploy telemedicine-based CCM in routine care at
CBOCs. In EBQI, both researchers and local staff participate fully in the
quality improvement process, with the researchers facilitating rather
than dictating implementation efforts [14–16]. Clinicians and admin-
istrators contribute local knowledge needed to tailor the evidence-
based practice for their own particular needs and organizational
capabilities. Researchers contribute knowledge of the clinical evidence
base, ensure ﬁdelity to the evidence base and supply materials,
procedures and tools needed for successful implementation.
Using the reach, efﬁcacy, implementation, adoption and mainte-
nance (RE-AIM) evaluation framework [17–20], we have previously
reported that the EBQI process resulted in positive outcomes at
implementation sites with regard to primary care provider adoption,
patient reach, clinical effectiveness (for those patients reached),
implementation ﬁdelity and maintenance [11]. The purpose of this
analysis is to estimate the “population impact” of the telemedicine-
based CCM program by comparing outcomes at implementation
sites to outcomes at control sites [21,22]. The population level
effectiveness of a clinical program depends on the interaction
between two of the RE-AIM implementation outcomes: reach and
effectiveness. To have a meaningful impact on the population, the
clinical program must reach a sufﬁcient proportion of the target
population, and the clinical program must be clinically effective for
those patients reached.
One approach to measuring the population level effectiveness of a
clinical program is to extrapolate the results of RCTs by specifying
algorithms that make assumptions about how trial inclusion/
exclusion criteria would affect reach into the target population if
the intervention was deployed in routine care. A good example of this
approach is presented by Zatzick et al. [21]. Another approach is to
directly compare clinical outcomes in the target population at
implementation sites with the clinical outcomes in an equivalent
population at control sites. While it is relatively straightforward to
measure the clinical outcomes of patients reached by the program, it
is much more difﬁcult to measure clinical outcomes for those patients
targeted, but not reached, at implementation sites and for equivalent
patients not targeted at control sites. More speciﬁcally, it is highly
resource intensive to collect primary data from all (or a sample of)
patients in the target population at both implementation and control
sites, especially if informed consent must be obtained. A good
example of this resource intensive approach is the well being
among veteran enhancement study (WAVES) evaluation of the
translating initiatives for depression into effective solutions (TIDES)
CCM implementation initiative [23].
An alternative approach, used in this analysis, is to compare
implementation sites and control sites with respect to process of care
measures derived from routinely collected data stored in administra-
tive datasets. This is only feasible if there is a process of care measure
available in the administrative data that is known to be correlated
with clinical outcomes. For example, Dijkstra et al. used HbA1c levels
(which are available in laboratory records) to estimate diabetic
outcomes in their implementation study [24]. For the case of
telemedicine-based CCM, previous research conducted in a popula-
tion of veterans treated for depression in CBOCs has documented that,controlling for casemix, patients with medication possession ratios
(MPR)≥0.9 were signiﬁcantly more likely to respond to treatment by
6 months (deﬁned as a 50% reduction in depression severity)
compared to those with MPRb0.9. The response rate among patients
with antidepressant MPR ≥0.9 was 28.9% compared to 15.9% among
those with MPRb0.9 [odds ratio (OR)=2.43, conﬁdence interval
(CI)95=1.29–4.57, P=.006] [25]. The objective of this research was to
estimate the population level effectiveness of telemedicine-based
CCM using this signiﬁcant correlation between antidepressant MPRs
derived from administrative pharmacy data and treatment response
rates. We hypothesized that, compared to the population of patients
at control CBOCs, the population of patients at implementation CBOCs
would have signiﬁcantly higher antidepressant MPRs and, by
assumption, higher treatment response rates.
2. Methods
2.1. Overview
This multisite pragmatic hybrid Type 3 effectiveness–implemen-
tation study employed a pre-post, quasi-experimental design with a
nonequivalent control group. The primary aim of a hybrid Type 3
effectiveness–implementation study design was to test an imple-
mentation strategy, while the secondary aim was to assess the
effectiveness of the clinical intervention in routine care [26]. The
results of the primary aim have been published previously [11]. This
analysis focuses on the secondary aim of assessing the clinical
effectiveness of telemedicine-based CCM. VA Medical Centers
(VAMCs) from two Veterans Integrated Service Networks (VISNs)
were chosen as implementation sites based on their number of
afﬁliated contract CBOCs, their willingness to participate and their
potential for success as perceived by VISN leadership. The implemen-
tation sites included 11 small (b1500 patients), medium (1500–5000
patients) or large (5000–10,000 patients) contract CBOCs associated
with three parent VAMCs. None of the implementation CBOCs were
staffed by an on-site psychiatrist. Using site-level matching, the
control group was chosen from a set of 15 small and medium contract
CBOCs lacking an on-site psychiatrist associated with the other seven
VAMCs located in the same two VISNs.
2.2. Clinical program
During the EBQI process, all three implementation VAMCs chose to
include one telephone depression nurse care manager and one
supervising telepsychiatrist on the CCM team. All three VAMCs
chose to exclude patients with serious mental illnesses, as well as
patients already receiving specialty mental health. All three VAMCs
chose to use the VA's Depression Case Finder tool to identify patients
with a new antidepressant prescription and to request consults (i.e.,
provider referrals) for these patients. In addition, primary care
providers were encouraged to refer other patients to the care
managers who they thought would beneﬁt from the CCM program.
The vast majority of patients referred to the CCM program were
prescribed antidepressant medications [11]. Care management activ-
ities at all three VAMCs included education/activation, barrier
assessment/resolution, symptom monitoring, medication adherence
monitoring, side-effects monitoring and self-management. Care
manager telephone encounters were scheduled every 2 weeks for
patients in the acute phase of treatment.
2.3. Target population
To estimate population impact, it is necessary to identify the target
population [22]. Because of the emphasis on antidepressant treatment
in the CCM program, we chose to deﬁne candidates as all patients
diagnosed with depression and prescribed an antidepressant
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123) of the patients at implementation sites with an encounter with a
depression care manager were prescribed an antidepressant medica-
tion. Nevertheless, this deﬁnition is likely to be an overly broad
approximation of the target population because many patients
prescribed with antidepressants are stable (i.e., asymptomatic) and
would not have been good candidates for referral to the CCMprogram.
However, symptom severity was not available in VA administrative
data and, thus, could not be used to further narrow the deﬁnition of
the target population for the analysis.2.4. Data sources
We extracted data from the Medical SAS Datasets at the Austin
Information Technology Center for ﬁscal years 2005–2009. Pharmacy
data were extracted from the Decision Support System National Data
Extracts [27] and patient characteristics were extracted from the
National Patient Care Database (NPCD) Outpatient Care Encounters
Clinic Stops Events [28]. Characteristics of veterans were extracted
from the NPCD datasets and included age, gender, marital status,
percentage service connection (the proportion of disability attribut-
able to military service) and ZIP code. The per capita income of each
patient's ZIP codewas determined from the US Census. In addition, ZIP
code was used to categorize patients as rural or urban based on the
rural–urban commuting area codes categorization Scheme A.2.5. Analytical sample
The start date for each implementation site was the date the ﬁrst
patient was enrolled in the CCM program and ranged from April 2006
to February 2008. The start date for control sites was the average of
the implementation site start dates in that VISN. Because of the lack of
site-level randomization, implementation sites may have been
systematically different from control sites in terms of structure,
process and outcomes. Therefore, it was necessary to use a pre-post
Quasi-experimental study design (see Fig. 1). The enrollment
postperiod was deﬁned as the 6 months after the implementation
start date at each site, and the follow-up postperiod was deﬁned as
months 6 to 12 after the implementation start date. The enrollment
preperiod was deﬁned as months 6 to 12 prior to the implementation
start date, and the follow-up preperiod was deﬁned as the 6 months
prior to the implementation start date. Index visits during the 6-
month pre- and postenrollment periods were deﬁned as the ﬁrst
primary care encounter (clinic stop code 323) with a primary or
secondary depression diagnosis (i.e., International Classiﬁcation of
Diseases-9 code of 296.2×, 296.3×, 298.0, 300.4, 309.1 or 311).
Patients were excluded from the analytical sample if they had a
specialty mental health encounter (primary clinic stop code: 500–
599) or a diagnosis of serious mental illness (schizophrenia, bipolar
disorder or substance dependence) at their index visit or during the 6
months prior to the index visit.Fig. 1. Pre-post quasi-experimental study design.Pharmacy data were extracted for all eligible patients. Prescrip-
tions for antidepressants below the therapeutic dose were dropped
(e.g., trazodone b300mg for sleep). The days supply of nonconcurrent
antidepressant prescription ﬁlls was summed to calculate the total
cumulative days supply during the 6 months after the index visit. The
days supply for antidepressant prescriptions written before the index
visit was prorated in the calculation of days supply if the days supply
carried over into the beginning of the 6-month enrollment postperiod.
Likewise, the days supply for antidepressant prescriptions written
near the end of the 6-month enrollment postperiod was prorated in
the calculation of days supply. For multiple concurrent prescriptions
of the same antidepressant, the days supply of each prescription ﬁll
was summed to calculate cumulative days supply. For multiple
concurrent prescriptions of different antidepressants, the days supply
of the earlier prescription was truncated (to account for possible
switching). MPR during the 6 months after the index visit was
calculated by dividing the cumulative days supply by 180 days.
Patients with an MPR=0 were excluded from the analytical sample.
Patients were classiﬁed as having adequate antidepressant adherence
if their MPR is ≥0.9. Based on a previous analysis of patients from the
same population/setting, this cutoff was found to be the most
predictive of treatment response compared to other cutoff points,
including the more traditionally used cutoff point of 0.8.
2.6. Site matching
There were 15 other contract CBOCs located in the same two VISNs
that also lacked on-site psychiatrists. To minimize differences
between sites, we used the nearest neighbor method to match control
CBOCs to implementation CBOCs with respect to MPR in the
preperiod. Speciﬁcally, we calculated the proportion of patients with
MPR≥0.9 during the preperiod separately for each site and matched
one control site to each implementation site for a total sample of 22
sites. This process resulted in dropping the four nonimplementation
CBOCs with the lowest rates of MPR≥0.9 in the preperiod.
2.7. Statistical analysis
Because there were statistically signiﬁcant differences across
implementation sites and control sites with respect to the proportion
of patients with MPR≥0.9 in the preperiod (despite site-level match-
ing), it was necessary to adjust statistically for preperiod differences in
the multivariate analysis. Therefore, we created a variable representing
the overall proportion of patients at each CBOC with MPR≥0.9 in the
preperiod and used it as a covariate in the multivariate analyses. Other
covariates included the patient's age, gender, marital status, service
connection, per capita income and rurality.
To test the hypothesis, we used PROC GENMOD (SAS Enterprise
Guide 4.1) to conduct a logistic regression analysis that controlled for
the clustering of patients within sites. The clustering of patients
within sites can cause signiﬁcant intraclass correlation that violates
the independence assumption of standard regressionmodels andmay
lead to incorrect inferences concerning the rejection of the null
hypotheses. We hypothesized that patients prescribed antidepres-
sants at implementation sites would be more likely to have MPR≥0.9
than patients at control sites.
2.8. Marginal effects and incremental effectiveness
We used the results of the logistic regression analysis to generate
the marginal effect associated with implementation and used it in a
formula to convert adjusted differences in the probability of having
MPR≥0.9 to expected differences in treatment response rates. To
generate the marginal effect of being treated at an implementation
site, we used the parameter estimates from the logistic regression to
calculate two predictions for each patient. The ﬁrst prediction was
Table 1
Characteristics of patients at study sites
Postperiod
Independent variables Full samplen=1588Mean (S.D.)/% Implementation CBOCsn=1132Mean (S.D.)/% Control CBOCsn=456Mean (S.D.)/% χ2/t P
Patient characteristics
Age 62.3 (14.5) 62.8 (14.7) 61.1 (13.9) t=−2.09 .04
Male 92.0% 92.5% 90.8% χ2=1.28 .26
Married 59.5% 58.8% 61.2% χ2=0.75 b .39
Rural 30.7% 27.8% 37.7% χ2=15.0 b .01
Per capita income 20,683 (9809) 20,812 (9754) 20,362 (9948) t=0.83 .41
Service connection 10–40% 15.2% 14.8% 16.2% χ2=0.55 .46
Service connection N50% 21.0% 19.8% 23.9% χ2=3.32 .07
Preperiod
Independent variables Full samplen=1488 Mean (S.D.)/% Implementation CBOCsn=1057 Mean (S.D.)/% Control CBOCsn=431Mean (S.D.)/% χ2/t P
Utilization
Primary care visits 2.36 (1.74) 2.04 (1.21) 3.17 (2.32) t=11.87 b .01
Depression primary care visits 1.44 (0.75) 1.36 (0.63) 1.63 (0.96) t=6.36 b .01
Mental health visits 1.29 (6.46) 1.38 (7.47) 1.08 (2.69) t=−81 .42
MPR 0.70 (0.29) 0.71 (0.28) 0.66 (0.29) t=−3.19 b .01
MPRN.9 36.6% 39.2% 30.2% χ2=10.70 b .01
Table 2
Multivariate logistic regression results for MPR ≥0.9
Variable OR Parameter estimate95% CI P value
Site
Control site [ref] – – –
Implementation site 1.38 [1.07, 1.78] .01
Preperiod MPR at site 8.48 [1.43, 50.2] .02
Age 1.01 [1.00, 1.02] b .01
Gender
Female [ref] – – –
Male 0.77 [0.58, 1.02] .07
Marital status
Not married [ref] – –
Married 1.22 [0.98, 1.52] .07
Rural 1.03 [0.85, 1.24] .79
Per capita incomea 1.00 [0.99, 1.01] .69
Service connection
b10% [ref] – –
10%-50% 0.96 [0.71, 1.31] .81
N50% 1.31 [0.86, 2.00] .20
a Measured in thousands of dollars.
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implementation site, and the second prediction was based on the
assumption that the patient was treated at a control site. The
difference between these two predictions represents the marginal
effect of being at an implementation site for that particular patient.
We then averaged the difference between the two predicted values
for each patient across all patients to generate an overall marginal
effect. A previous RCT conducted in the same patient population
reported that CBOC patients diagnosed with depression with MPR
≥0.9 have signiﬁcantly higher odds [OR=2.4, 95% CI=(1.29–4.57),
P=.006] of responding to treatment by 6 months compared to CBOC
patients diagnosed with depression with MPRb0.9 [25]. Based on this
ﬁnding, it was determined that a 10% point increase (from 25% to 35%)
in the percentage of patients with MPR ≥0.9 would translate into an
expected 1.3% point increase in response rates. Using the CI for the
MPR OR [95% CI=(1.29–4.57)], the 95% CI for this 10% increase would
be 0.3%–2.5%. Applying that formula to the estimated marginal effect
yields the expected difference in postperiod response rates between
patients treated at implementation and control sites. This expected
difference represents the population level incremental effectiveness,
which we then converted into the number-needed-to-treat (NNT)
statistic and corresponding 95% CI.
3. Results
The average number of patients treated was 3848 (range: 1325 to
7411) at the 11 implementation sites and 2394 (range: 712 to 4991)
at the 11 control sites. There were 1558 patients (n=1132 at
implementation sites and n=456 at control sites) who had an index
visit during the 6-month enrollment postperiod with a depression
diagnosis and an active antidepressant prescription sometime during
the 6-month follow-up period. There were few signiﬁcant differences
between patients at implementation and control sites (see Table 1).
Patients at implementation sites were statistically, but not substan-
tially, older than patients at control sites (t=−2.09, P=.04). Likewise,
patients at implementation sites were signiﬁcantly less rural than
patients at control sites (χ2=15.0, Pb .01).
Of the 1132 patients prescribed an antidepressant at implementa-
tion sites, 10.3% (n=116) had an encounter with a depression care
manager documented in the administrative data in the 6 months after
their index visit. Thus, the telemedicine-based CCM program only
reached about 1 in 10 of the targeted patients. In the preperiod,
implementation sites had a signiﬁcantly (χ2=10.70, Pb .01) higher
percentage of patients (39.2%)withMPR≥0.9 than control sites (30.2%).
The proportion of patients with MPR≥0.9 increased between the pre-and postperiods at implementation sites but remained essentially
unchanged at control sites. Thus, in the postperiod, implementation
sites also had a signiﬁcantly (χ2=18.3, Pb .01) higher percentage of
patients with MPR≥0.9 (42.5%) than control sites (30.9%).
In the multivariate logistic analysis that controlled for patient
characteristics and preperiod site differences in MPR≥0.9 (Table 2),
patients at implementation sites had a signiﬁcantly higher probability
of having MPR≥0.9 than patients at control sites [OR=1.38, 95% CI=
(1.07–1.78), P=.01]. Of the covariates, the variable representing the
proportion of CBOC patients in the preperiod with MPR≥0.9 was the
biggest predictor [OR=8.48, 95% CI=(1.43–50.22), P=.02) of a
patient having MPR≥0.9 in the postperiod. Age was also a signiﬁcant
and positive predictor of having MPR≥0.9.
Using the parameter estimates from the logistic regression, the
MPR marginal effect of being treated at implementation sites
compared to control sites is 7.35%. Applying the MPR to treatment
response conversion formula indicates that a 7.35% point increase in
the proportion of patients with MPR≥0.9 translates into an expected
1% point increase in treatment response rate [95% CI=(0.2%–1.8%)]. In
other words, for every 100 veterans prescribed an antidepressant at
sites with telemedicine-based CCM, there would be one additional
treatment responder compared to those sites without telemedicine-
based CCM. The NNT is 100 [95% CI=(500–56)].
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Few studies have statistically estimated the overall effectiveness of
implementing a clinical intervention on the mental health symptoms
of a population of patients. The population impact of a clinical
intervention depends on both its reach into the targeted population
and its effectiveness for those reached [21]. It can be extremely
difﬁcult to measure population impact because both reach and
effectiveness are difﬁcult to measure at the population level. To
estimate population level effectiveness, previous studies have either
collected primary symptom data from implementation and control
sites at great expense [23] or used differences in symptoms between
intervention and control groups observed in RCTs along with
assumptions about how trial inclusion/exclusion criteria would
impact reach into the target population if the intervention were
deployed in routine care [21]. In contrast, this study measured MPRs
(derived from administrative data) at implementation and control
sites and used a previous estimate of the correlation between MPR
and treatment response to calculate population level effectiveness.
Each of these three approaches has its strengths and limitations. The
ﬁrst approach is likely to have the best internal and external validity,
but it is expensive to compile the large sample sizes needed to detect
statistically the small differences in clinical outcomes that are likely to
be observed at the population level. The second approach uses an
internally valid estimate of clinical effectiveness for those patients
reached but relies on making accurate assumptions about how trial
inclusion/exclusion criteria would impact reach during subsequent
implementation in routine care. The third approach (used in this
analysis) uses an accurate estimate of reach into the target population
during implementation but relies on having a valid estimate of how a
process of care measure derived from administrative data contributes
to clinical outcomes. In this study, the accuracy of this estimate is
enhanced by the fact that the correlation between process and
outcomewas estimated using data from a study that was conducted in
the same population and clinical setting.
Partly due to the broad deﬁnition concerning which patients
would have been good candidates for telemedicine-based CCM, the
reach into the target population was relatively low (10%). Primary
care providers only referred patients to the program who they
thought would beneﬁt from the telemedicine-based CCM program.
Presumably, many of the patients treated with antidepressants who
were not referred to the program were stable on medications during
the time period and would not have beneﬁtted clinically from the
program. In terms of the population impact (reach*effectiveness),
we estimate that 33.85% of patients prescribed an antidepressant at
sites without telemedicine-based CCM programs would have
MPR≥0.9 while 41.20% would have MPR≥0.9 at sites with
telemedicine-based CCM programs (a difference of 7.4% points).
These relatively low levels of medication possession are similar to
those observed in other depression CCM studies conducted in the VA
setting [29,23]. In addition, the 7.4% point difference in rates of
MPR≥0.9 between implementation and control sites observed in this
study is similar to the 5.2% point difference in rates of MPR≥0.8
observed in the WAVES implementation study of depression CCM
[23]. Given that only 10.3% of patients prescribed antidepressants at
implementation sites had a documented encounter with a care
manager, the ﬁnding that the rate of MPR≥0.9 was 7.4% points
higher at implementation sites compared to control sites could be
interpreted a number of different ways. First, it is possible that
primary care providers referred patients to the care managers who
were very likely to experience medication adherence problems and
the care managers were able to help most of these patients remain
adherent (i.e., 71.8%=7.4%/10.3%). This explanation is supported by
the fact that the telemedicine-based CCM program was speciﬁcally
designed to promote antidepressant adherence. However, it is also
possible that there was a spillover effect such that patients notreferred to care managers also beneﬁted from the telemedicine-
based CCM program (e.g., raised awareness in the clinic about
antidepressant adherence). However, given the short time frame
(6 months), this explanation is unlikely. Third, it is possible that the
care managers had encounters with patients that were not
documented in the electronic health record (i.e., coding errors)
and, thus, that the reach of the program was actually larger than the
observed 10.3%.
The higher probability of patients having MPR≥0.9 translated
into a population level effectiveness of telemedicine-based CCM
implementation of 0.01, or equivalently an NNT=100. This is a very
small effect size, and its magnitude primarily reﬂects the low reach
into the target population rather than the ineffectiveness of the CCM
program (which had good outcomes for those patients reached) [11].
Nevertheless, this effect size, when applied to the very large
population of CBOC patients prescribed with antidepressants,
suggests that implementing telemedicine-based CCM could have a
clinically meaningful impact at a larger scale. Considering that about
2.5 million primary care patients are treated at CBOCs annually, that
6.9% of CBOC patients screen positive for depression annually [12]
and that 70% of these ﬁll an antidepressant prescription [25], this
level of population effectiveness would result in an estimated
additional 1208 veterans responding to treatment each year
compared to usual care. This effect could be improved if implemen-
tation strategies were developed that increased the reach of
telemedicine-based CCM.
For policy makers to interpret the population level effectiveness, it
will also be necessary to consider the costs of implementation.
Population level cost-effectiveness analyses will need to compare
the cost and beneﬁts of implementing a clinical intervention across
the entire target population and not just those reached. While the
estimated effectiveness of the telemedicine-based CCM program was
small when measured at the population level, we can also expect that
the costs (when distributed across the entire target population) will
also be relatively small. Thus, the cost-effectiveness of the telemed-
icine-based CCM program could fall well below standard thresholds
for deployment when measured at the population level.
An important limitation of this study is that the population level
impact of telemedicine-based CCMwas estimated using data collected
during the early phase of implementation. Thus, these ﬁndings do not
reﬂect the steady state of the implementation initiative, which may
have become more or less successful over time. Another limitation is
that the formula used to convert differences in MPR into differences in
treatment response rates was based on observational data, which
could have been subject to selection bias. Similarly, if depression CCM
has other mechanisms of action besides antidepressant adherence
(e.g., self-management, social support), we may have underestimated
population level effectiveness [13,30]. In addition, the accuracy of our
estimate of the marginal effect of CCM on MPR relied on the internal
validity of our quasi-experimental study design. Internal validity may
have been compromised by the fact that VAMCswere chosen based on
their willingness to participate and their potential for success as
perceived by VISN leadership. Despite these limitations, this study
makes an important contribution to the growing ﬁeld of comparative
effectiveness research, as it is one of only a handful of studies that
have measured the population level effectiveness of a clinical
intervention deployed in routine care.
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